endoscopy device News
-
Medical Device Company Lazurite™ Named a 2021 Top 10 Endoscopy Device Provider by MedTech Outlook Magazine
Medical device and technology company Lazurite Holdings LLC has been recognized by MedTech Outlook magazine as a 2021 Top 10 Endoscopy Device Provider for its ArthroFree™ wireless camera system for minimally invasive surgery. MedTech Outlook describes itself as a platform that bridges the spectrum between medtech technology providers and healthcare facilities and medical institutes. In ...
-
Lazurite™ Announces FDA 510(k) Submission for its ArthroFree™ Wireless Camera System; is Recognized by AngelMD as One of the Best Startups of 2021
Medical device and technology company Lazurite Holdings LLC today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its ArthroFree™ wireless camera system for minimally invasive surgery, and that the submission has been accepted for review. The company also announced that early-stage healthcare investment platform AngelMD named it ...
-
Scivita Medical Raises Nearly RMB0.4 Billion in Series a Funding Round and Strives to Build a World-leading Platform for Innovative Products in Endoscope and Related Fields
Scivita Medical Technology Co., Ltd. ('Scivita Medical*) today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures with contribution from Matrix Partners China, Medtronic, Chengwei Capital and ...
-
Stockholders Approve Delisting from the Official List
BOSTON and SYDNEY — 22 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of Stockholders on 21 June 2020 and, in accordance with ASX Listing Rule 3.13.2, is pleased to confirm that each of the ...
-
Placement of $750,000 Unsecured Convertible Promissory Note & Update on Potential Financing and Special Meeting
BOSTON and SYDNEY — 19 June 2020 — GI Dynamics® Inc. (ASX:GID) (“GID” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$750,000 Unsecured Convertible Promissory Note to Crystal Amber Fund Limited (“Crystal Amber”), the ...
-
Further Extension of Maturity Date of June 2017 Note and Financing Update
BOSTON and SYDNEY — 1 July 2020 — GI Dynamics® Inc. (ASX:GID) (”the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the extension of the maturity date of the Senior Secured Convertible Promissory Note issued to Crystal Amber Fund Limited (“Crystal ...
-
Further Delisting Update
BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, provides the following update regarding the removal of the Company from the Official List of the Australian Securities Exchange (“ASX”) (“Official List”). ...
-
Conversion of June 2017 Convertible Note
BOSTON and SYDNEY — 15 July 2020 — GI Dynamics® Inc. (ASX:GID) (the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, advises that it has received a notice of conversion from Crystal Amber Fund Limited (“Crystal Amber”) (a Related Party for Australian Securities Exchange ...
-
GI Dynamics Completes Initial Closing of a $10 Million Series A Preferred Stock Financing from Crystal Amber
BOSTON — September 10, 2020 — GI Dynamics® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of Series A Preferred Stock led by Crystal Amber Fund Limited (“Crystal Amber”), ...
-
GI Dynamics Appoints New Chief Executive Officer and Board of Directors
BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI Dynamics, Mark Lerdal as chairman of the Board of Directors (“the Board”) and ...
-
Miamitech Startup Spotlight: Dalent Aims to Improve Sinus Surgery Experience, Outcome and Cost
If you’ve ever had an awful sinus infection, you know how painful, and quite frankly, how much of a drag it is. But most of us don’t have Chronic Sinusitis, which consists of a sinus infection lasting longer than 3 months (despite treatment), according to the Mayo Clinic. That being said, 11.6% of the American population does, says the CDC. For years, if doctors couldn’t bring ...
-
GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data from the Association of British Clinical Diabetologists (ABCD) Worldwide ...
-
EndoLogic Acquires Renzapride from Alizyme, plc
EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, has acquired the worldwide rights to the clinical-stage asset, renzapride, from Alizyme, plc. Renzapride has been in clinical development for use as a prokinetic agent for the gastrointestinal tract. EndoLogic plans on developing the compound for the treatment of gastroparesis. ...
-
Lumendi Reports Successful Enrollment Closure of Its Dilumen Endolumenal Interventional Platform (EIP) Study
A STUDY EVALUATING ENDOSCOPIC PROCEDURE TIME REMOVING COMPLEX COLORECTAL POLYPS SHOWS SUPERIORITY OF DILUMEN OVER CONTROL GROUP. Connecticut-based medical device innovator Lumendi, LLC reports that its 1:1 randomized trial of the DiLumen Endoluminal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study ...
By Lumendi Ltd.
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Early Trial Data Show Promise in Endoscopic Procedure Time Study
A STUDY EVALUATING ENDOSCOPIC PROCEDURE TIME REMOVING COMPLEX COLORECTAL POLYPS SHOWS SUPERIORITY OF LUMENDI’S DILUMEN DEVICE OVER A CONTROL GROUP. Connecticut-based medical device innovator Lumendi LLC reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The ...
By Lumendi Ltd.
-
Atlantic Healthcare plc acquires global rights to renzapride for the treatment of gastrointestinal motility disorders
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases, today announced that the Company has entered into an agreement to acquire the global rights to renzapride from EndoLogic LLC (“EndoLogic”). Renzapride is a ...
-
Lumendi Receives 510(K) Clearance for Dilumen Ik Endolumenal Interventional Knife
Connecticut-based medical device innovator Lumendi, LLC (http://www.lumendi.com) has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the DiLumen Ik™ Endolumenal Interventional Knife, a sterile, single-use, disposable monopolar electrosurgical device for cutting, dissecting, and cauterizing tissue within the digestive tract during endoscopic procedures. ...
By Lumendi Ltd.
-
Lumendi Reports First Incisionless Appendectomy Using Double-Balloon Endolumenal Interventional Platform
Patient reported no post-procedure pain and resumed regular activity day after procedure Connecticut-based medical device innovator Lumendi, LLC reports the first endoscopic appendectomy using its DiLumenTM Endolumenal Interventional Platform (EIP). A patient underwent the purely endoscopic endolumenal appendectomy to remove a lesion previously identified at the appendiceal orifice. ...
By Lumendi Ltd.
-
Olympus Extends Portfolio of EndoTherapy Solutions at DDW
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today the availability of several new endoscopic therapeutic devices, to be unveiled at the upcoming Digestive Disease Week conference May 6-9 in Chicago, Ill. The expansion of the market leading offerings is a signal of the Olympus ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you